Bayer
NEWS
In July 2017, Bayer launched a three-year, Phase III ASTEROID clinical trial of vilaprisan in patients with symptomatic uterine fibroids, with the intention of recruiting more than 3,600 patients in 900 sites in 40 countries.
Noting that from 1998 to 2017 there have been about 146 failed shots at developing drugs for Alzheimer’s disease, PhRMA released a report on the state of the industry. This would not lead most people to think there are many reasons to be optimistic about Alzheimer’s disease research, but the report does believe there are good reasons to be.
Bayer will cut 12,000 jobs as it prepares an overhaul of its business that includes exiting its animal health business as it deals with the fallout from its $63 billion acquisition of Monsanto. Additionally, the company said it will sell its 60 percent stake in Germany-based site services provider Currenta.
The U.S. Food and Drug Administration (FDA) gave the green light late Monday to Bayer oncology drug Vitrakvi, a first-of-its-kind TRK inhibitor, after late-stage clinical trial results showed a 75 percent overall response rate and 22 percent complete response rate across various solid tumors.
A prostate cancer drug jointly developed by healthcare giant Bayer and Finland-based Orion can slow the spread of the disease, according to late-stage study results announced early Wednesday.
Dr. Amin Al Amiri: the Programs are part of ministry’s initiatives during ‘Year of Zayed’ to provide quality of care to patients
German company Bayer AG is laying off 227 staffers at its manufacturing plant in Berkeley, California. Most of the cuts took place on October 3.
Here’s a look at who shook things up in the world of pharma and biotech this week.
Following AbbVie Lawsuit, Government Scrutinizes Industry-Provided Drug Educational Support Services
A federal investigation is underway into whether or not the nursing and other medical services provided by some pharmaceutical companies to doctor’s offices actually violate the law due to serving an illegal commercial service.
JOBS
IN THE PRESS